coronary artery disease - revascularization with drug eluting stent - acute myocardial infarction clinical trials results meta-analysis

<h1> <a href="TM29-79-revascularization with drug eluting stent-coronary artery disease" > <strong>coronary artery disease</strong> - revascularization with drug eluting stent </a> - acute myocardial infarction trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t6564.htm"> PASSION, 2006 </a> <br> ISRCTN65027270 </td> <td> Taxus Express2<br>  <i>versus</i> <br> Express2 or Liberté </td> <td> Myocardial Infarction with ST-Segment Elevation </td> <td> follow-up 12 months (5y)<br> n=310/309<br> Parallel groups<br> open <br> The Netherlands </td> </tr> <tr> <td> <a href="../TRC_t6565.htm"> HAAMU-STENT, 2006 </a> <br> </td> <td> Taxus Express<br>  <i>versus</i> <br> Bare-metal-stent </td> <td> AMI - STEMI patients undergoing PCI </td> <td> follow-up 12 months<br> n=70/75<br> Parallel groups<br> open <br> Finland </td> </tr> <tr> <td> <a href="../TRC_t6573.htm"> TYPHOON, 2006 </a> <br> NCT00232830 </td> <td> Cypher or CypherSelect<br>  <i>versus</i> <br> any commerciallyavailable uncoated stent </td> <td> AMI </td> <td> follow-up 12 months<br> n=356/359<br> Parallel groups<br> open <br> Worldwide (15 countries) </td> </tr> <tr> <td> <a href="../TRC_t6574.htm"> SESAMI, 2007 </a> <br> NCT00288210 </td> <td> Cypher<br>  <i>versus</i> <br> BX stent, Cordis </td> <td> AMI </td> <td> follow-up 12 months<br> n=160/160<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="../TRC_t6578.htm"> MISSION, 2008 </a> <br> ISRCTN62825862 </td> <td> Cypher<br>  <i>versus</i> <br> Vision </td> <td> primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h) </td> <td> follow-up 12 months<br> n=158/152<br> Parallel groups<br> single-blind <br> the Netherlands </td> </tr> <tr> <td> <a href="../TRC_t6589.htm"> PROSIT, 2006 </a> <br> </td> <td> SES Cordis<br>  <i>versus</i> <br> PES Boston Scientific </td> <td> AMI or persistent ischaemia 12-24h </td> <td> follow-up 1 year<br> n=154/154<br> Parallel groups<br> open <br> Korea </td> </tr> <tr> <td> <a href="../TRC_t6590.htm"> SORT OUT II, 2008 </a> <br> NCT00388934 </td> <td> Cypher stent<br>  <i>versus</i> <br> Taxus stent(Boston Scientific Corp) </td> <td> Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina) </td> <td> follow-up <br> n=1065/1033<br> Parallel groups<br> open <br> Denmark. </td> </tr> <tr> <td> <a href="../TRC_t6719.htm"> ZEST AMI (vs PES), 2009 </a> <br> NCT00422565 </td> <td> zotarolimus-eluting stent (Endeavor) <br>  <i>versus</i> <br> paclitaxel-eluting stent (Taxus Liberté) </td> <td> Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours </td> <td> follow-up 1 year (mean)<br> n=108/110<br> <br> open <br> Korea </td> </tr> <tr> <td> <a href="../TRC_t7411.htm"> Díaz de la Llera, 2007 </a> <br> </td> <td> sirolimus-eluting stents<br>  <i>versus</i> <br> uncoated stents </td> <td> primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation </td> <td> follow-up 1y<br> n=60/54<br> Parallel groups<br> open <br> Spain </td> </tr> <tr> <td> <a href="../TRC_t8658.htm"> DEDICATION, 2008 </a> <br> NCT00192868 </td> <td> DES currently used with or without distal protection <br>  <i>versus</i> <br> BMS with or without distal protection </td> <td> patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction </td> <td> follow-up 8 mo (15 mo, 3y)<br> n=313/313<br> Factorial plan<br> open <br> Denmark. </td> </tr> <tr> <td> <a href="../TRC_t8669.htm"> HORIZONS-AMI Stent, 2008 </a> <br> </td> <td> paclitaxel-eluting stents (Taxus)<br>  <i>versus</i> <br> BMS (Express) </td> <td> ST-elevation myocardial infarction </td> <td> follow-up 1 year<br> n=2257/749<br> Factorial plan<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t8670.htm"> ZEST AMI (vs SES), 2009 </a> <br> NCT00422565 </td> <td> zotarolimus-eluting stent (Endeavor) <br>  <i>versus</i> <br> sirolimus-eluting stents (Cypher) </td> <td> Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours </td> <td> follow-up 1 year (mean)<br> n=108/110<br> Parallel groups<br> open <br> Korea </td> </tr> <tr> <td> <a href="../TRC_t8775.htm"> SORT-OUT-3, 2010 </a> <br> </td> <td> Zotarolimus-eluting stents<br>  <i>versus</i> <br> sirolimus-eluting stents (SES) </td> <td> Patients With Coronary Artery Disease undergoing PCI for any indication </td> <td> follow-up 9 months (18 mo)<br> n=1162/1171<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9322.htm"> GENIUS-STEMI, 2009 </a> <br> </td> <td> endothelial progenitor cell capture stent<br>  <i>versus</i> <br> cobalt chromium stent </td> <td> patients with ST-elevation myocardial infarction </td> <td> follow-up 6 months<br> n=50/50<br> Parallel groups<br> NA <br> </td> </tr> <tr> <td> <a href="../TRC_t9772.htm"> PASEO, 2009 </a> <br> </td> <td> paclitaxel-eluting stents and sirolimus-eluting stents<br>  <i>versus</i> <br> bare metal stent </td> <td> patients with ST-elevation myocardial infarction within 12 hours from symptom onset </td> <td> follow-up 4.3 years<br> n=180/90<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9978.htm"> DEBATER (SES vs BMS), 2009 </a> <br> </td> <td> sirolimus-eluting stents<br>  <i>versus</i> <br> bare-metal stents </td> <td> patients undergoing PCI for STEMI withon 12 hours </td> <td> follow-up 1 y<br> n=424/446<br> Factorial plan<br> <br> </td> </tr> </table> <h2>References</h2> <p> <b>PASSION, 2006 : </b> Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson MPaclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. <i>N Engl J Med 2006;355:1105-13</i> [PMID 16971717] </p> <p> <b>PASSION, 2006 : </b> Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ <i>EuroIntervention 2008 May;4:64-70</i> [PMID 19112781] </p> <p> <b>HAAMU-STENT, 2006 : </b> Tierala I, Syvaenne M, Kupari MRandomised comparison of apaclitaxel-eluting and a bare metal stent in STEMI-PCI. TheHAAMU-STENT-study <i>Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics; Washington, DC;Oct 2227, 2006. Abstract 178.</i> [PMID ] </p> <p> <b>TYPHOON, 2006 : </b> Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode CSirolimus-eluting versus uncoated stents in acute myocardial infarction. <i>N Engl J Med 2006;355:1093-104</i> [PMID 16971716] </p> <p> <b>SESAMI, 2007 : </b> Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini RRandomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). <i>J Am Coll Cardiol 2007;49:1924-30</i> [PMID 17498576] </p> <p> <b>SESAMI, 2007 : </b> Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli RMaintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction) Trial. <i>J Am Coll Cardiol 2010 Feb 23;55:810-814</i> [PMID 20170821] 10.1016/j.jacc.2009.09.046 </p> <p> <b>MISSION, 2008 : </b> van der Hoeven BL, Liem S, Jukema JW, et al.Prospectiverandomised trial to evaluate the effi cacy and safety of drug-elutingstents versus barem-metal stents for the treatment of acutemyocardial infarction (the MISSION! intervention study) <i>AnnualScientifi c Meeting of the American Heart Association. Chicago, IL,USA; Nov 1215, 2006.</i> [PMID ] </p> <p> <b>MISSION, 2008 : </b> van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJSirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. <i>J Am Coll Cardiol 2008 Feb 12;51:618-26</i> [PMID 18261680] </p> <p> <b>PROSIT, 2006 : </b> Lee JH, Kim HS, Lee SW, et al.Prospective randomized trial of asirolimus eluting versus a paclitaxel eluting stent for the treatmentof acute ST-elevation myocardial infarction <i>Annual Scientifi cMeeting of the American College of Cardiology; Atlanta, GA, USA;March 1114, 2006.</i> [PMID ] </p> <p> <b>PROSIT, 2006 : </b> Kornowski RDrug-eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. <i>Catheter Cardiovasc Interv 2008 Jul 1;72:33-5</i> [PMID 18561153] </p> <p> <b>PROSIT, 2006 : </b> Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Cho Y, Lee N, Rhee KS, Ko JK, Seong IWProspective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. <i>Catheter Cardiovasc Interv 2008 Jul 1;72:25-32</i> [PMID 18412270] </p> <p> <b>SORT OUT II, 2008 : </b> Galloe AM.prospective multi-center, large-scale, randomized trialof paclitaxel- and sirolimus-eluting stents in real-world lesions <i>Annual Scientifi c Meeting of the Transcatheter CardiovascularTherapeutics; Washington, DC; Oct 2227, 2006</i> [PMID ] </p> <p> <b>SORT OUT II, 2008 : </b> Galle AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamki K, Junker A, Aare J, Abildgaard U, Ravkilde J, Engstrm T, Jensen JS, Andersen HR, Btker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrm SZ, StepComparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. <i>JAMA 2008;299:409-16</i> [PMID 18230778] </p> <p> <b>STRATEGY, 2005 : </b> Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode CSirolimus-eluting versus uncoated stents in acute myocardial infarction. <i>N Engl J Med 2006;355:1093-104</i> [PMID 16971716] </p> <p> <b>STRATEGY, 2005 : </b> Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari RTirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. <i>JAMA 2005 May 4;293:2109-17</i> [PMID 15870414] </p> <p> <b>STRATEGY, 2005 : </b> Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari RTwo-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. <i>J Am Coll Cardiol 2007;50:138-45</i> [PMID 17616297] </p> <p> <b>STRATEGY, 2005 : </b> Valgimigli M, Mittmann N, Cohen DJ, Campo G, Isogai PK, Seung SJ, Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R, A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. <i>Int J Cardiol 2008;128:53-61.</i> [PMID 17698218] 10.1016/j.ijcard.2007.05.021 </p> <p> <b>ZEST AMI (vs PES), 2009 : </b> Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJComparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. <i>Am J Cardiol 2009;104:1370-6</i> [PMID 19892052] </p> <p> <b>Díaz de la Llera, 2007 : </b> Daz de la Llera LS, Ballesteros S, Nevado J, Fernndez M, Villa M, Snchez A, Retegui G, Garca D, Martnez ASirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. <i>Am Heart J 2007;154:164.e1-6</i> [PMID 17584571] </p> <p> <b>MULTISTRATEGY, 2008 : </b> Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari RComparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. <i>JAMA 2008;299:1788-99</i> [PMID 18375998] </p> <p> <b>DEDICATION, 2008 : </b> Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klvgaard L, Kaltoft A, Andersen B, Thuesen H, Engstrm T, Btker HE, Saunamki K, Krusell LR, Jrgensen E, Hansen HH, Christiansen EH, Ravkilde J, Kber L, Kofoed KF, Terkelsen CJ, Lassen JFDrug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. <i>Circulation 2008 Sep 9;118:1155-62</i> [PMID 18725489] </p> <p> <b>ZEST AMI (vs SES), 2009 : </b> Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJComparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. <i>Am J Cardiol 2009;104:1370-6</i> [PMID 19892052] </p> <p> <b>SORT-OUT-3, 2010 : </b> Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbæk H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrøm T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrøm SZ, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Johnsen SP, Jensen LO, SørenEfficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. <i>Lancet 2010 Mar 13;:</i> [PMID 20231034] 10.1016/S0140-6736(10)60208-5 </p> <p> <b>GENIUS-STEMI, 2009 : </b> Cervinka A Randomized Comparison of Genous Stent Versus Chromium-Cobalt Stent for Treatment of ST-Elevation Myocardial Infarction: A 6-Month Clinical, Angiographic, and IVUS Follow-up: GENIUS-STEMI trial <i>ACC.09/i2, Orlando, FL, March 2009</i> [PMID ] </p> <p> <b>PASEO, 2009 : </b> Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato GThe PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. <i>JACC Cardiovasc Interv 2009 Jun;2:515-23</i> [PMID 19539255] </p> <p> <b>PASEO, 2009 : </b> Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca GLong-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. <i>Circulation 2009;120:964-72</i> [PMID 19720939] </p>